Raptor lines up $50 million loan ahead of decision date on rare disease drug

San Francisco Business Time | By Ron Leuty

Closing in on an FDA decision date on its treatment for a potentially fatal rare kidney disease, Raptor Pharmaceutical Corp. signed a $50 million loan with HealthCare Royalty Partners.